-
-
Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials
-
-
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitati
-
-
Effects of Tofacitinib on Bone Marrow Edema, Synovitis, and Erosive Damage in Methotrexate-Naive Patients with Early Active Rheumatoid Arthritis (Duration <= 2 Years): Results of an Exploratory Phase 2 MRI Study
-
-
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
-
-
Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate: Results of Two Phase 3 Studies
-
-
Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: a 24-Month Phase 3 Study